WellPoint Plans CER Guidance, Building On Progress With Outcomes Data
Executive Summary
WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research
You may also be interested in...
WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies
WellPoint has released guidelines for the submission and evaluation of comparative effectiveness research that it will use in reviewing drugs for its formulary
WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies
WellPoint has released guidelines for the submission and evaluation of comparative effectiveness research that it will use in reviewing drugs for its formulary
Senate Considers Revised Comparative Effectiveness Plan In Reform Bill
Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor